Fresh Off Its Launch, Novartis’s Rhapsido Notches Phase III Win In Chronic Inducible Urticaria

 
• By Sushmita Panda
  
Novartis Makes $3bn Bet On Synnovation’s PI3Kα Inhibitor SNV4818
(Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D